Avii,
I have no idea how the protocol was established. I'm uncertain if the vaccine could have been given earlier, but if it could be, I suspect it will be once approved. Whether it was the company, or the regulators who dictated when the vaccine could initially be administered, I have no idea, but once that is decided, it only makes sense to determine which patient is best suited to the trial at the point at which treatment can be initiated.
I gather that it takes about a week to make the vaccine once you have the surgery. If the leukapheresis is done in a timely manner, potentially the vaccine could be administered roughly a week post surgery. As I said, I don't know why this wasn't the protocol, but as long as it wasn't, I can understand not selecting patients for the trial until you determine how they've done in preceding treatment.
It's unfortunate, but many with GBM have only a few months to live once it's discovered. I cannot say that our vaccine can benefit those who's disease has progressed that far prior to its discovery. I cannot blame the company for not initiating treatment in patients who's illness has been deemed to have progressed too far to gain benefit. In the future, hopefully tests that provide for earlier detection of GBM, as well as many other cancers will be developed.
Gary
Market Data 
Markets 
AI
